CD8A and neoplasm: D’Alise et al. demonstrated that the gorilla Ad vaccine targeting tumor neoepitopes combined with αPD-1 in a mouse model could increase neoantigen-specific CD8+ T cells, improving immunogenicity and antitumor efficacy while potentially alleviating resistance to the PD-1 blockade [119].